Loading...
•
Mar 31, 2022
Royalty Pharma Q1 2022 Earnings Report
Royalty Pharma reported strong Q1 2022 results with a 15% increase in Adjusted Cash Receipts and reaffirmed 2022 guidance.
Key Takeaways
Royalty Pharma reported a decrease in net cash provided by operating activities to $460 million, while total income and other revenues decreased 2% to $562 million. However, Adjusted Cash Receipts increased 15% to $605 million and Adjusted EBITDA grew 15% to $556 million. The company reaffirmed its 2022 Adjusted Cash Receipts guidance of $2,225 million to $2,300 million.
Adjusted Cash Receipts increased 15% to $605 million, driven by cystic fibrosis franchise, Tysabri and recent royalty acquisitions.
Adjusted EBITDA grew 15% to $556 million, driven by strong growth in Adjusted Cash Receipts.
Announced transactions of up to $450 million in Q1 2022, including an expanded partnership with Cytokinetics.
2022 guidance reaffirmed: Adjusted Cash Receipts expected to be $2,225 to $2,300 million.
Revenue by Segment
Forward Guidance
Royalty Pharma reaffirmed its 2022 Adjusted Cash Receipts guidance of $2,225 million to $2,300 million, excluding new transactions announced after the date of this release.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...